Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Precision Medicine And The Advent Of The “Niche Buster”: An Interview With GSK’s Paolo Paoletti

Executive Summary

The president of GlaxoSmithKline Oncology talked with “The Pink Sheet” about precision medicine, regulatory climate change, the need to provide value for payers and the company’s commitment to double cancer survival globally over the next 10 years.


Related Content

Many New Oncology Drugs In 2012, With Prices That Test The Limits
GSK Is Getting Ready For A Return To The ’90s
Glaxo Confident In Output From Its Revamped R&D Engine
GSK’s Promacta Cleared For Use With Interferon In Hep C Patients
Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s Zelboraf
GSK’s Oncology Expansion Heavily Dependent On Dabrafenib, Trametinib
FDA Opts For Full, Rather Than Accelerated, Approval Of GSK’s Votrient In Sarcoma
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts